妊娠合并肺动脉高压的早期识别及临床管理
Early Identification and Clinical Management of Pregnancy Complicated with Pulmonary Hypertension
DOI: 10.12677/ACM.2024.143699, PDF,    科研立项经费支持
作者: 郑 芳, 邓 玮*:重庆医科大学附属第二医院全科医学科,重庆
关键词: 妊娠肺动脉高压早期识别临床管理Pregnancy Pulmonary Hypertension Early Identification Clinical Management
摘要: 肺动脉高压最终会进展为循环、呼吸衰竭,而妊娠状态加重心肺负担,妊娠合并肺动脉高压是危及母体及胎儿的妊娠并发症,症状不典型,早期难以识别,死亡率高。超声心动图较右心导管检查而言,具有简单、方便、无创的优点,临床常用。妊娠合并肺动脉高压患者一经诊断,应进行多学科管理,制定个体化、全程的诊疗方案。
Abstract: Pulmonary hypertension will eventually lead to circulatory and respiratory failure, and the state of pregnancy increases the burden of heart and lung. Pregnancy complicated with pulmonary hyper-tension is a pregnancy complication that endangers the mother and fetus. The symptoms are atypi-cal and difficult to identify in the early stage, and cause high mortality. Compared with right cardiac catheterization, echocardiography is simple, convenient and non-invasive, and is commonly used in clinic. Once patients are diagnosed, they should carry out multi-disciplinary management and for-mulate individual and whole-process diagnosis and treatment plans, and choose the appropriate operation and anesthesia to terminate the pregnancy in time.
文章引用:郑芳, 邓玮. 妊娠合并肺动脉高压的早期识别及临床管理[J]. 临床医学进展, 2024, 14(3): 291-297. https://doi.org/10.12677/ACM.2024.143699

参考文献

[1] 中华医学会呼吸病学分会肺栓塞与肺血管病学组, 中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会, 全国肺栓塞与肺血管病防治协作组, 等. 中国肺动脉高压诊断与治疗指南(2021版) [J]. 中华医学杂志, 2021, 101(1): 11-51.
[2] 蒲杰. 我国孕产妇死因构成的变迁[J]. 实用妇产科杂志, 2021, 37(3): 161-165.
[3] Roos-Hesselink, J., Baris, L., Johnson, M., et al. (2019) Pregnancy Outcomes in Women with Cardio-vascular Disease: Evolving Trends over 10 Years in the ESC Registry of Pregnancy and Cardiac Disease (ROPAC). European Heart Journal, 40, 3848-3855. [Google Scholar] [CrossRef] [PubMed]
[4] D’souza, R.D., Silversides, C.K., Tomlinson, G.A., et al. (2020) Assessing Cardiac Risk in Pregnant Women with Heart Disease: How Risk Scores Are Created and Their Role in Clinical Practice. Canadian Journal of Cardiology, 36, 1011-1021. [Google Scholar] [CrossRef] [PubMed]
[5] 中华医学会妇产科学分会产科学组. 妊娠合并心脏病的诊治专家共识(2016) [J]. 中华妇产科杂志, 2016, 51(6): 401-409.
[6] D’alto, M., Di Maio, M., Romeo, E., et al. (2022) Echocardiographic Probability of Pulmonary Hypertension: A Validation Study. European Respiratory Journal, 60, Arti-cle ID: 2102548. [Google Scholar] [CrossRef] [PubMed]
[7] 董倩, 黄玮, 游小钧. 超声心动图测量肺动脉压力校正方法的研究[J]. 中国循环杂志, 2019, 34(7): 693-697.
[8] 胡思宇, 金镇. 妊娠合并先天性心脏病伴肺动脉高压孕妇的母婴结局[J]. 中国医科大学学报, 2022, 51(7): 643-647.
[9] Schuster, M., Muller, J., Schwarz, E.I., et al. (2023) Oxygen Therapy in Pulmonary Vascular Disease: A Systematic Review, Meta-Analysis, and Comment. Heart Failure Clinics, 19, e1-e11. [Google Scholar] [CrossRef] [PubMed]
[10] Callejo, M., Barbera, J.A., Duarte, J., et al. (2020) Impact of Nutrition on Pulmonary Arterial Hypertension. Nutrients, 12, Article 169. [Google Scholar] [CrossRef] [PubMed]
[11] Pellicori, P., Platz, E., Dauw, J., et al. (2021) Ultrasound Imaging of Congestion in Heart Failure: Examinations beyond the Heart. European Journal of Heart Failure, 23, 703-712. [Google Scholar] [CrossRef] [PubMed]
[12] Varrias, D., Spanos, M., Kokkinidis, D.G., et al. (2023) Venous Throm-boembolism in Pregnancy: Challenges and Solutions. Vascular Health and Risk Management, 19, 469-484. [Google Scholar] [CrossRef
[13] Turner, J.M., Russo, F., Deprest, J., et al. (2022) Phosphodiester-ase-5 Inhibitors in Pregnancy: Systematic Review and Meta-Analysis of Maternal and Perinatal Safety and Clinical Out-comes. BJOG, 129, 1817-1831. [Google Scholar] [CrossRef] [PubMed]
[14] Qian, H., Chen, Q., Liang, L., et al. (2021) A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects. Drug Design, Development and Therapy, 15, 2947-2959. [Google Scholar] [CrossRef
[15] Zhang, C. and Jing, S. (2021) Therapeutic Antibody Approach for Pulmonary Arterial Hypertension. International Journal of Cardiology and Cardiovascular Diseases, 1, 15-19. [Google Scholar] [CrossRef
[16] Dai, Y., Qiu, Z., Ma, W., et al. (2021) Long-Term Effect of a Vac-cine Targeting Endothelin-1 Receptor Type a in Pulmonary Arterial Hypertension. Frontiers in Cardiovascular Medicine, 8, Article 683436. [Google Scholar] [CrossRef] [PubMed]
[17] Torres, F., Farber, H., Ristic, A., et al. (2019) Efficacy and Safety of Ralinepag, a Novel Oral IP Agonist, in PAH Patients on Mono or Dual Background Therapy: Results from a Phase 2 Randomised, Parallel Group, Placebo-Controlled Trial. European Respiratory Journal, 54, Article ID: 1901030. [Google Scholar] [CrossRef] [PubMed]
[18] Mulvaney, E.P., Reid, H.M., Bialesova, L., et al. (2020) NTP42, a Novel Antagonist of the Thromboxane Receptor, Attenuates Experimentally Induced Pulmonary Arterial Hy-pertension. BMC Pulmonary Medicine, 20, Article No. 85. [Google Scholar] [CrossRef] [PubMed]
[19] Condon, D.F., Agarwal, S., Chakraborty, A., et al. (2022) Novel Mechanisms Targeted by Drug Trials in Pulmonary Arterial Hypertension. Chest, 161, 1060-1072. [Google Scholar] [CrossRef] [PubMed]
[20] Boehm, M., Tian, X., Ali, M.K., et al. (2021) Improving Right Ventricular Function by Increasing BMP Signaling with FK506. American Journal of Respiratory Cell and Molecular Biology, 65, 272-287. [Google Scholar] [CrossRef
[21] Hoeper, M.M., Badesch, D.B., Ghofrani, H.A., et al. (2023) Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. American Journal of Respiratory Cell and Molecular Biology, 388, 1478-1490. [Google Scholar] [CrossRef
[22] Dhoble, S., Patravale, V., Weaver, E., et al. (2022) Comprehensive Review on Novel Targets and Emerging Therapeutic Modalities for Pulmonary Arterial Hypertension. International Journal of Pharmaceutics, 621, Article ID: 121792. [Google Scholar] [CrossRef] [PubMed]
[23] Bader, M. (2020) Inhibition of Serotonin Synthesis: A Novel Therapeutic Paradigm. Pharmacology & Therapeutics, 205, Article ID: 107423. [Google Scholar] [CrossRef] [PubMed]
[24] Li, B., Teng, C., Yu, H., et al. (2023) Alleviating Experi-mental Pulmonary Hypertension via Co-Delivering FoxO1 Stimulus and Apoptosis Activator to Hyperproliferating Pul-monary Arteries. Acta Pharmaceutica Sinica B, 13, 2369-2382. [Google Scholar] [CrossRef] [PubMed]
[25] 苗明汇. 椎管内麻醉和全身麻醉对妊娠合并肺动脉高压患者妊娠结局的影响[J]. 中国现代药物应用, 2020, 14(15): 70-72.
[26] Chen, W., Luo, J., Chen, J., et al. (2023) Effect of Multidisciplinary Team (MDT) Centred on Pregnant Women with Pulmonary Hypertension on Treatment and Outcomes of Pregnancy. BMC Pulmonary Medicine, 23, Arti-cle No. 62. [Google Scholar] [CrossRef] [PubMed]
[27] 中华预防医学会心身健康学组, 中国妇幼保健协会妇女心理保健技术学组. 孕产妇心理健康管理专家共识(2019年) [J]. 中国妇幼健康研究, 2019, 30(7): 781-786.
[28] 钟赋真, 徐文, 王雷, 等. 孕产期心理筛查异常情况分析[J]. 中国妇幼健康研究, 2021, 32(8): 1123-1128.
[29] 姜蕾, 朱素君, 彭中华, 等. PHQ-9、GAD-7用于孕妇心理健康调查结果分析[J]. 中国妇幼健康研究, 2021, 32(8): 1172-1177.
[30] Zhang, Q., Zhu, F., Shi, G., et al. (2023) Maternal Outcomes among Pregnant Women with Congenital Heart Disease-Associated Pulmonary Hypertension. Circulation, 147, 549-561. [Google Scholar] [CrossRef